Compare
Tirzepatide vs Retatrutide
Two incretin-based peptides in the same broad family, but at very different stages of development. This page compares what the peer-reviewed literature currently supports on each — regulatory status, receptor targets, evidence tier, and headline efficacy from published phase-3 trials.
Last reviewed 2026-07-11
Investigational compound involved
Retatrutide is investigational. It has not been approved by the FDA, EMA, or any other regulatory authority. Long-term safety, comparative effectiveness, and manufacturing standards are still being established. Nothing on this page is a recommendation to use either compound.
Regulatory status
Tirzepatide
FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). EMA-approved.
Retatrutide
Investigational. Not approved by any regulatory authority. Currently in phase-3 development.
3 citations in this row
Evidence tier
Tirzepatide
Strong. Multiple published, peer-reviewed phase-3 trials with tens of thousands of participant-years.
Retatrutide
Emerging. Published phase-2 trials in obesity and type 2 diabetes; phase-3 program ongoing.
5 citations in this row
Receptor targets
Tirzepatide
GLP-1 receptor agonist and GIP receptor agonist (dual).
Retatrutide
GLP-1 receptor agonist, GIP receptor agonist, and glucagon receptor agonist (triple).
1 citation in this row
Approved indications
Tirzepatide
Type 2 diabetes mellitus (Mounjaro). Chronic weight management with a BMI threshold (Zepbound).
Retatrutide
None. Studied in obesity and type 2 diabetes phase-3 trials.
2 citations in this row
Headline efficacy in published trials
Tirzepatide
SURMOUNT-1 (2022): mean body-weight reduction of −20.9 % at 72 weeks on the 15 mg dose in adults with obesity without diabetes.
Retatrutide
Phase-2 (Jastreboff, 2023): mean body-weight reduction of −24.2 % at 48 weeks on the 12 mg dose. Phase-3 outcomes remain unpublished.
2 citations in this row
Safety-data maturity
Tirzepatide
Well-characterized. Post-marketing surveillance ongoing since 2022. GI adverse events dominate; boxed warning for thyroid C-cell tumors in rodents.
Retatrutide
Limited. Adverse-event profiles from phase-2 trials show GI events consistent with the incretin class; increases in heart rate observed at higher doses. Long-term safety unknown.
3 citations in this row
Formulation and presentation
Tirzepatide
Prefilled multi-dose pen; ready-to-use solution; no reconstitution required in the licensed presentation.
Retatrutide
Trial supply distributed as a lyophilized powder requiring reconstitution before subcutaneous injection.
1 citation in this row
The two peptides sit at different points on the same research arc. Tirzepatide's role is defined by regulator-reviewed evidence and years of post-marketing use. Retatrutide's role is still being written in ongoing phase-3 trials.
References
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)· Rosenstock J, Wysham C, Frías JP, et al. · 2021
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)· Frías JP, Davies MJ, Rosenstock J, et al. · 2021
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)· Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
- Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)· Aronne LJ, Sattar N, Horn DB, et al. · 2024
- FDA Prescribing Information — MOUNJARO (tirzepatide) injection· U.S. Food and Drug Administration · 2022
- FDA Prescribing Information — ZEPBOUND (tirzepatide) injection· U.S. Food and Drug Administration · 2023
- Mounjaro (tirzepatide) — European Public Assessment Report (EPAR)· European Medicines Agency · 2022
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist· Willard FS, Douros JD, Gabe MBN, et al. · 2020
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial· Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial· Rosenstock J, Frías JP, Jastreboff AM, et al. · 2023
Continue exploring
Editorial paths through the library. Pick one and follow the trail.
Compare
Semaglutide vs Tirzepatide
Two of the most extensively studied incretin-based therapies — approved and marketed in the same therapeutic areas, but with different receptor profiles, different phase-3 programs, and different published outcomes. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
BPC-157 vs TB-500
These two peptides are the most-discussed pair in the tissue-repair conversation, and they are also the most-conflated. In practice they share none of what usually justifies grouping compounds: their origins are unrelated, their mechanisms are unrelated, and the shape of the evidence supporting each is structurally different. This page walks through those distinctions.
→
Compare
KPV vs GHK-Cu
Two small, endogenously-derived peptides that get grouped in discussions about anti-inflammatory and skin peptides. They share molecular scale — both are tripeptides — and their mechanisms are both proposed to be intracellular rather than classical receptor-mediated. Everything else about their evidence structures, use cases, and regulatory status differs, in ways that are worth reading precisely.
→
Compare
Tesamorelin vs Sermorelin
Two GHRH analogues built for the same fundamental job — stimulating the pituitary's own pulsatile release of growth hormone — but at very different points in structure, half-life, and regulatory history. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
CJC-1295 (No DAC) vs Sermorelin
Two GHRH(1-29)-based signals. Sermorelin is the native sequence; CJC-1295 No DAC is the same sequence with four amino acid substitutions that resist enzymatic degradation. This page compares what the peer-reviewed literature currently supports on each.
→
Compare
CJC-1295 No DAC vs CJC-1295 DAC
The two forms share an identical GHRH(1-29) backbone with the same four amino acid substitutions. The Drug Affinity Complex (DAC) — a single maleimidopropionic acid linker that covalently binds serum albumin — is the only chemical difference. Every downstream pharmacologic property flows from that one addition. This page reads out those differences precisely.
→
Compare
AOD-9604 vs Semaglutide
Two compounds pursued as pharmacological approaches to weight loss, from opposite starting points and with opposite clinical results. AOD-9604 was designed as a lipolytic fragment of human growth hormone; its 2007 phase 2b did not meet its primary endpoint and its pharmaceutical program was discontinued. Semaglutide came from the incretin research tradition, obtained FDA approval for chronic weight management in 2021, and produced a large clinical evidence base. This page presents the two side by side to make each visible in the other's context.
→
Categories
Fat Loss & Metabolism
Compounds studied for body-composition, glycaemic control, and metabolic health.
→
Categories
Repair & Regeneration
Compounds studied for wound healing, tissue repair, and musculoskeletal recovery.
→